Literature DB >> 594794

Diagnostic implications of markedly elevated erythrocyte sedimentation rate: a reevaluation.

D J Wyler.   

Abstract

To reevaluate the diagnostic significance of a markedly elevated erythrocyte sedimentation rate (ESR), the clinical diagnosis associated with an ESR of 100 mm/hr or greater was retrospectively analyzed in 200 patients at the Massachusetts General Hospital. In contrast to previously reported experiences in the the American literature suggesting a high frequency (58 percent) of malignant disease in such patients, the present study found infections to be the most frequently associated diseases (35 percent), while malignant disease accounted for only 15 percent of the patients. Review of the foreign literature similarly suggested infection rather than malignancy as a major association with markedly elevated ESRs. It is concluded that an ESR greater than or equal to 100 mm/hr has little diagnostic specificity and should not of itself dictate evaluation for occult malignancy in most patients.

Entities:  

Mesh:

Year:  1977        PMID: 594794     DOI: 10.1097/00007611-197712000-00015

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  Increased erythrocyte sedimentation rate and a splenic mass.

Authors:  J V Hirschmann; S Patterson; J G Drachman; H Rosen; W C Liles
Journal:  West J Med       Date:  1994-12

2.  Incorporating geographical factors with artificial neural networks to predict reference values of erythrocyte sedimentation rate.

Authors:  Qingsheng Yang; Kevin M Mwenda; Miao Ge
Journal:  Int J Health Geogr       Date:  2013-03-12       Impact factor: 3.918

3.  18F-fluorodeoxyglucose positron emission tomography in elderly patients with an elevated erythrocyte sedimentation rate of unknown origin.

Authors:  Karel-Jan D F Lensen; Alexandre E Voskuyl; Conny J van der Laken; Emile F I Comans; Dirkjan van Schaardenburg; Alex B Arntzenius; Ton Zwijnenburg; Frank Stam; Michelle Gompelman; Friso M V D Zant; Anneke Q A van Paassen; Bert J Voerman; Frits Smit; Sander Anten; Carl E Siegert; Arjen Binnerts; Yvo M Smulders
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.